A case of unusual substance abuse causing myeloneuropathy

Spinal Cord

Volumn 45, Issue 4, 2007, Pages 314-317

  Shulman, R M ^a   Geraghty, T J ^a   Tadros, M ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Cobalamin antagonists inhibitors; Myeloneuropathy; Myelopathy; Nitrous oxide bulbs; Nitrous oxide toxicity; Subacute combined degeneration; Substance abuse; Vitamin B12 deficiency

Indexed keywords

NITRIC OXIDE;

ADULT; BRAIN DISEASE; CASE REPORT; COGNITIVE DEFECT; CYANOCOBALAMIN DEFICIENCY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; INHALANT ABUSE; KIDNEY FAILURE; LUNG EMBOLISM; NEUROLOGICAL COMPLICATION; NEUROPATHY; NEUROTOXICITY; PRIORITY JOURNAL; REHABILITATION CARE; REVIEW; SELF CARE; SPINAL CORD DISEASE; SUBSTANCE ABUSE; TEACHING HOSPITAL; WALKING; WALKING AID; WHEELCHAIR;

ADULT; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NITROUS OXIDE; SUBACUTE COMBINED DEGENERATION; SUBSTANCE-RELATED DISORDERS; VITAMIN B 12 DEFICIENCY;

EID: 34147180599     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sj.sc.3101962     Document Type: Review

References (14)

1. Ahn SC, Brown AW. Cobalamin deficiency and subacute combined degeneration after nitrous oxide anaesthesia: a case report. Arch Phys Med Rehabil 2005; 86: 150-153.
2. Lai NY, Silbert PL, Erber WN, Rijks CJ. 'Nanging': another cause of nitrous oxide neurotoxicity. Med J Aust 1997; 166: 166.
3. Scalabrino G. Cobalamin (vitamin B(12)) in subacute combined degeneration and beyond: traditional interpretations and novel theories. Exp Neurol 2005; 192: 463-479.
4. Buccellato FR et al. Myelinolytic lesions in spinal cord of cobalamin deficient rats are TNF-α-mediated. FASEB J 1999; 13: 297-304.
5. Timms SR, Cure JK, Kurent JE. Subacute combined degeneration of the spinal cord: MR findings. AJNR Am J Neuroradiol 1993; 14: 1224-1227.
6. Beltramello A et al. Subacute combined degeneration of the spinal cord after nitrous oxide anaesthesia: role of magnetic resonance imaging. J Neurol Neurosurg Psychiatry 1998; 64: 563-564.
7. Sahenk Z, Mendell JR, Couri D, Nachtman J. Polyneuropathy from inhalation of N2O cartridges through a whipped-cream dispenser. Neurology 1978; 28: 485-487.
8. Henry-Edwards S. Inhalant Policy: What can we learn from the National Drug Strategy?. Paper presented at the Inhalant Use and Disorder Conference convened by the Australian Institute of Criminology, Townsville, Australia; 7-8 July 2003.
9. Australian Institute of Health and Welfare 2004 National Drug Strategy Household Survey. (AIHW cat. no. PHE 57) Canberra, (Australia); April 2005.
10. Ng J, O'Grady G, Pettit T, Frith R. Nitrous oxide use in first-year students at Auckland University. Lancet 2003; 361: 1349-1350.
11. Stacy CB, Di Rocco A, Gould RJ. Methionine in the treatment of nitrous-oxide-induced neuropathy and myeloneuropathy. J Neurol 1992; 239: 401-403.
12. Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine (Baltimore) 1991; 70: 229-245.
13. Butzkueven H, King JO. Nitrous oxide myelopathy in an abuser of whipped cream bulbs. J Clin Neurosci 2000; 7: 73-75.
14. Brett A. Myeloneuropathy from whipped cream bulbs presenting as conversion disorder. Aust N Z J Psychiatry 1997; 31: 131-132.